Jon Ernstoff, MD
Gastroenterology · Meriden, CTNPI 1598789653
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 91 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 14 manufacturers reported payments, led by AbbVie at 29.0% of the total. Reporting peaked in 2019 at $959 and has fallen 83.8% since, to $155 in 2023. That places this record below the midpoint for gastroenterology clinicians in CT, where the typical reported total is $3,356.
Across 91 payments — averaging $17.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$456
- Takeda Pharmaceuticals U.S.A., Inc.$300
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$209
- Johnson & Johnson$129
- Intercept Pharmaceuticals, Inc.$92
- Gilead$78
- plus $311 from 8 others
What the payments were for
- Food & beverage$1,575100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 27 | $456 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $300 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $209 |
| Johnson & Johnson | 7 | $129 |
| Intercept Pharmaceuticals, Inc. | 4 | $92 |
| Gilead | 5 | $78 |
| UCB, Inc. | 3 | $68 |
| Bristol Myers Squibb | 3 | $55 |
| Merck | 3 | $49 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Alfasigma USA, Inc. | 2 | $34 |
| QOL Medical, LLC | 2 | $31 |
| Shire North American Group Inc | 1 | $19 |
| Pfizer | 1 | $16 |
How this compares
$1,575 in reported general payments places this provider in the 35th percentile of 326 gastroenterology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Famotidine | 33 | $848 |
| Pantoprazole Sodium | 53 | $812 |
| Omeprazole | 17 | $234 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Meriden
- Housein WazazMeriden$108K
- Paul FeuerstadtHamden$1M
- James FrestonFarmington$772K
- Loren LaineWest Haven$451K
- Martin HoffmanHartford$317K
- Colin SwalesHartford$285K
- Joseph CappaGlastonbury$200K
- Renuka UmashankerHamden$197K
- David HassHamden$173K
- Michael EinsteinHartford$139K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.